TrialCancer communications (London, England)2022

Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3).

Yuankai Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.